Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-20T15:16:25.527Z Has data issue: false hasContentIssue false
  • English
  • Français

Topical treatment of eczematous external otitis involving the ear canal: long-term results of a trial comparing pimecrolimus 1 per cent versus clobetasone butyrate 0.05 per cent

Published online by Cambridge University Press:  07 January 2022

Z Nemeth ,
E Verga Open the ORCID record for E Verga [Opens in a new window]  and
R Verdolini
Z Nemeth
Affiliation:
Department of ENT, Princess Alexandra Hospital NHS Trust, Harlow, UK
E Verga*
Affiliation:
Department of Dermatology, Princess Alexandra Hospital NHS Trust, Harlow, UK
R Verdolini
Affiliation:
Department of Dermatology, Princess Alexandra Hospital NHS Trust, Harlow, UK
*
Author for correspondence: Dr Emanuele Verga, Department of Dermatology, Princess Alexandra Hospital NHS Trust, Harlow, UK E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Eczematous external otitis is a common chronic condition that can have a significant impact on the life of sufferers, causing constant discomfort and pruritus, and leading to sleep deprivation. Treatment is based on the use of topical steroids, moisturisers and occasionally antibiotics. Results, however, can be disappointing, especially over the long term.

Methods

This study compared the long-term response to pimecrolimus, administered to a group of 11 patients, against clobetasone butyrate, administered to an equivalent number of patients. Response to the treatment was assessed and statistically analysed at 3 and 12 months.

Conclusion

Whereas the degree of improvement following the use of pimecrolimus and clobetasone butyrate was similar for the two groups at month 3, a highly statistically significant difference was documented at month 12, with a much greater and sustained improvement in the pimecrolimus group.

Keywords

Eczematous DisordersExternal OtitisTopical AdministrationPimecrolimusCalcineurin InhibitorsSteroidsClobetasone ButyrateExternal EarEar Canal
Type
Main Article
Information
The Journal of Laryngology & Otology , Volume 136 , Issue 7 , July 2022 , pp. 635 - 638
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press on behalf of J.L.O. (1984) LIMITED

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Dr E Verga takes responsibility for the integrity of the content of the paper

References

Cicek, D, Kandi, B, Bakar, S, Turgut, D. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. J Dermatolog Treat 2009;20:344–9CrossRefGoogle ScholarPubMed
Gupta, AK, Versteeg, SG. Topical treatment of facial seborrheic dermatitis: a systematic review. Am J Clin Dermatol 2017;18:193–213CrossRefGoogle ScholarPubMed
Ang-Tiu, CU, Meghrajani, CF, Maano, CC. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials. Expert Rev Clin Pharmacol 2012;5:91–7CrossRefGoogle ScholarPubMed
Clark, GW, Pope, SM, Jaboori, KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician 2015;91:185–90Google ScholarPubMed
Avena-Woods, C. Overview of atopic dermatitis. Am J Manag Care 2017;23:S115–23Google ScholarPubMed
Eichenfield, LF, Beck, L. Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003;111:1154–68CrossRefGoogle ScholarPubMed
Torres, T, Ferreira, EO, Goncalo, M, Mendes-Bastos, P, Selores, M, Filipe, P. Update on atopic dermatitis. Acta Med Port 2019;32:606–13CrossRefGoogle ScholarPubMed
Meurer, M, Lubbe, J, Kapp, A, Schneider, D. The role of pimecrolimus cream 1% (Elidel®) in managing adult atopic eczema. Dermatology 2007;215:18–26CrossRefGoogle Scholar
Warshaw, EM, Wohlhuter, RJ, Liu, A, Zeller, SA, Wenner, RA, Bowers, S et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol 2007;57:257–64CrossRefGoogle ScholarPubMed
Gisondi, P, Ellis, CN, Girolomoni, G. Pimecrolimus in dermatology: atopic dermatitis and beyond. Int J Clin Pract 2005;59:969–74CrossRefGoogle ScholarPubMed
Ozden, MG, Tekin, NS, Ilter, N, Ankarali, H. Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face an open-label study. Am J Clin Dermatol 2010;11:51–4CrossRefGoogle ScholarPubMed
Zhao, J, Sun, W, Zhang, C, Wu, J, Le, Y, Huang, C et al. Comparison of different regimens of pimecrolimus 1% cream in the treatment of facial seborrheic dermatitis. J Cosmet Dermatol 2018;17:90–4CrossRefGoogle ScholarPubMed
Firooz, A, Solhpour, A, Gorouhi, F, Daneshpazhooh, M, Balighi, K, Farsinejad, K et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol 2006;142:1066–7CrossRefGoogle ScholarPubMed
Rigopoulos, D, Ioannides, D, Kalogeromitros, D, Gregoriou, S, Katsambas, A. Primecrolimus cream 1% vs betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis. A randomised open-label clinical trial. Br J Dermatol 2004;151:1071–5CrossRefGoogle Scholar
Cunha, PR. Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids. Acta Derm Venereol 2006;86:69–70Google ScholarPubMed
Kesser, BW. Assessment and management of chronic otitis externa. Curr Opin Otolaryngol Head Neck Surg 2011;19:341–7CrossRefGoogle ScholarPubMed
Caffier, PP, Harth, W, Mayelzadeh, B, Haupt, H, Sedlmaier, B. Tacrolimus: a new option in therapy-resistant chronic external otitis. Laryngoscope 2007;117:1046–52CrossRefGoogle ScholarPubMed
Harth, W, Caffier, PP, Mayelzadeh, B, Haupt, H, Sedlmaier, B, Richard, G. Topical tacrolimus treatment for chronic dermatitis of the ear. Eur J Dermatol 2007;17:405–11Google ScholarPubMed